Ann Rhoads

Ann Rhoads is a healthcare finance executive with over 25 years of experience. She was the Chief Financial Officer for Forty Seven, Inc. (Nasdaq: FTSV), a clinical-stage, immuno-oncology company from 2018 until its sale to Gilead for $4.9 billion in 2020. From 2010 to early 2017, she was Executive Vice President and Chief Financial Officer at Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing and commercializing products for the treatment of orphan and central nervous system disorders.

Prior to joining Zogenix, Ms. Rhoads was Chief Financial Officer and Senior Vice President for Premier, Inc. from 2000 to 2009 (now Nasdaq: PINC). Ms. Rhoads started her career as an investment professional with Merrill Lynch and the Sprout Group, the venture capital affiliate of Donaldson, Lufkin & Jenrette (now part of Credit Suisse).

Ms. Rhoads received a master's in Business Administration from the Harvard Graduate School of Business Administration and a Bachelor of Science in Business Administration from the University of Arkansas.